Biogen is dropping controversial Alzheimer’s drug Aduhelm
Jan 31, 2024
Biogen said it will shift its focus to a newer Alzheimer’s drug, Leqembi, which it markets in a partnership with Japan-based Eisai. Leqembi received FDA approval last year.
Long-term care pharmacies forced to borrow to buy resident drugs, close as intermediaries tighten grip...
By
Kimberly Marselas
Apr 08, 2024
Long-term care resident access to prescription drugs is being squeezed as several market and regulatory factors have combined to increase the power that pharmacy benefit managers have over the specialized...
Future of promising Alzheimer’s treatment Leqembi could depend on access to data reporting, analysis:...
By
Aaron Dorman
Feb 16, 2024
Organizations must have clearer guidelines as to how data on lecanemab will be collected, pooled and studied, policy experts say.
Antibiotics not helpful for cough due to lower respiratory tract infection
Apr 25, 2024
Despite patient beliefs, no effect was seen on the severity or duration of the cough.
ACP: Next-generation antibiotics underused for gram-negative infections
Apr 22, 2024
41.5% of difficult-to-treat resistance episodes were treated exclusively with traditional agents.
ACP: Recommendations developed for newer type 2 diabetes medications
Apr 22, 2024
A strong recommendation was given for the addition of an SGLT-2 or GLP-1 agonist to metformin, and lifestyle modifications.
One in seven drug supply chain issue reports tied to drug shortages
Apr 10, 2024
Supply disruptions increased for drugs with and without reports at the start of the COVID-19 pandemic.
Denosumab linked to severe hypocalcemia in dialysis-dependent seniors
Jan 25, 2024
The risk increased for severe and very severe hypocalcemia for female dialysis-dependent Medicare patients aged 65 years or older.
Focus on briefs: Medication management
Apr 12, 2024
PharMerica selects SinguLab to deliver pharmacogenomics solutions, Drug shortages shrouded in mystery
More seniors may be willing to take deprescribing advice
By
John Hall
Apr 12, 2024
Providers, however, must continue to check their motivation in cutting back on certain prescriptions, pharmacy experts caution.